Lexicon Pharmaceuticals
- Country
- πΊπΈUnited States
- Ownership
- Public, Subsidiary
- Established
- 1995-01-01
- Employees
- 285
- Market Cap
- $621.7M
- Website
- http://www.lexpharma.com
- Introduction
Lexicon Pharmaceuticals, Inc. engages in the discovery, development, and commercialization of pharmaceutical products for the treatment of human disease. Its drug candidates include: LX9211, an orally-delivered small molecule drug candidate, as a treatment for neuropathic pain, and Sotagliflozin, a treatment for heart failure and type 1 diabetes. The company was founded by Brian P. Zambrowicz and Arthur T. Sands on July 7, 1995 and is headquartered in The Woodlands, TX.
A Phase 1 Study to Evaluate the Effects of Omeprazole and Famotidine on the Absorption of Telotristat Ethyl in Healthy Subjects
- Conditions
- Drug-drug Interaction
- Interventions
- First Posted Date
- 2017-10-05
- Last Posted Date
- 2018-04-25
- Lead Sponsor
- Lexicon Pharmaceuticals
- Target Recruit Count
- 32
- Registration Number
- NCT03302845
- Locations
- πΊπΈ
Covance Clinical Research Unit, Dallas, Texas, United States
Safety, Tolerability and Pharmacodynamic Activity of Sotagliflozin in Hemodynamically Stable Participants With Worsening Heart Failure
- First Posted Date
- 2017-09-25
- Last Posted Date
- 2021-05-11
- Lead Sponsor
- Lexicon Pharmaceuticals
- Target Recruit Count
- 32
- Registration Number
- NCT03292653
- Locations
- πΊπΈ
Investigational Site Number 8400005, La Jolla, California, United States
πΊπΈInvestigational Site Number 8400001, New Haven, Connecticut, United States
πΊπΈInvestigational Site Number 8400007, Rochester, Minnesota, United States
Efficacy and Safety of Sotagliflozin Versus Placebo in Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control While Taking Insulin Alone or With Other Oral Antidiabetic Agents
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- First Posted Date
- 2017-09-18
- Last Posted Date
- 2021-05-11
- Lead Sponsor
- Lexicon Pharmaceuticals
- Target Recruit Count
- 571
- Registration Number
- NCT03285594
- Locations
- πΊπΈ
Investigational Site Number 8406028, Mesa, Arizona, United States
πΊπΈInvestigational Site Number 8406013, Phoenix, Arizona, United States
πΊπΈInvestigational Site Number 8406020, Phoenix, Arizona, United States
Safety and Efficacy Study of Sotagliflozin on Glucose Control in Participants With Type 2 Diabetes, Moderate Impairment of Kidney Function, and Inadequate Blood Sugar Control
- Conditions
- Type 2 Diabetes MellitusChronic Kidney Disease Stage 3
- Interventions
- Drug: Placebo
- First Posted Date
- 2017-08-08
- Last Posted Date
- 2021-06-25
- Lead Sponsor
- Lexicon Pharmaceuticals
- Target Recruit Count
- 787
- Registration Number
- NCT03242252
- Locations
- πΊπΈ
Investigational Site Number 8404018, Birmingham, Alabama, United States
πΊπΈInvestigational Site Number 8404045, Guntersville, Alabama, United States
πΊπΈInvestigational Site Number 8404004, Phoenix, Arizona, United States
A Study to Evaluate Safety and Effects of Sotagliflozin 400 and 200 mg on Glucose Control in Participants With Type 2 Diabetes, Severe Impairment of Kidney Function and Inadequate Blood Sugar Control
- Conditions
- Type 2 Diabetes MellitusChronic Kidney Disease Stage 4
- Interventions
- Drug: Placebo
- First Posted Date
- 2017-08-08
- Last Posted Date
- 2021-06-25
- Lead Sponsor
- Lexicon Pharmaceuticals
- Target Recruit Count
- 277
- Registration Number
- NCT03242018
- Locations
- πΊπΈ
Investigational Site Number 8405033, Guntersville, Alabama, United States
πΊπΈInvestigational Site Number 8405005, Phoenix, Arizona, United States
πΊπΈInvestigational Site Number 8405007, Little Rock, Arkansas, United States
Efficacy and Safety of Sotagliflozin Versus Placebo in Participants With Type 2 Diabetes Mellitus on Background of Sulfonylurea Alone or With Metformin
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- First Posted Date
- 2017-02-28
- Last Posted Date
- 2021-05-11
- Lead Sponsor
- Lexicon Pharmaceuticals
- Target Recruit Count
- 507
- Registration Number
- NCT03066830
- Locations
- πΊπΈ
Investigational Site Number 8403003, Litchfield Park, Arizona, United States
πΊπΈInvestigational Site Number 8403018, Peoria, Arizona, United States
πΊπΈInvestigational Site Number 8403009, Greenbrae, California, United States
Efficacy and Safety of Sotagliflozin Versus Placebo in Patients With Type 2 Diabetes Mellitus on Background of Metformin
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- First Posted Date
- 2016-10-06
- Last Posted Date
- 2021-05-11
- Lead Sponsor
- Lexicon Pharmaceuticals
- Target Recruit Count
- 518
- Registration Number
- NCT02926950
- Locations
- πΊπΈ
Investigational Site Number 8402003, Birmingham, Alabama, United States
πΊπΈInvestigational Site Number 8402017, Birmingham, Alabama, United States
πΊπΈInvestigational Site Number 8402052, Phoenix, Arizona, United States
Efficacy and Safety of Sotagliflozin Versus Placebo in Patients With Type 2 Diabetes Mellitus Not Currently Treated With Antidiabetic Therapy
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- Drug: Placebo
- First Posted Date
- 2016-10-06
- Last Posted Date
- 2021-06-21
- Lead Sponsor
- Lexicon Pharmaceuticals
- Target Recruit Count
- 399
- Registration Number
- NCT02926937
- Locations
- πΊπΈ
Investigational Site Number 8401049, Tucson, Arizona, United States
πΊπΈInvestigational Site Number 8401026, Tucson, Arizona, United States
πΊπΈInvestigational Site Number 8401028, Anaheim, California, United States
Study to Evaluate Sotagliflozin in Subjects With Varying Degrees of Renal Function
- First Posted Date
- 2016-01-06
- Last Posted Date
- 2019-02-26
- Lead Sponsor
- Lexicon Pharmaceuticals
- Target Recruit Count
- 50
- Registration Number
- NCT02647918
- Locations
- πΊπΈ
Lexicon Investigational Site, Saint Paul, Minnesota, United States
A Phase 3 Study to Evaluate the Safety of Sotagliflozin in Patients With Type 1 Diabetes Who Have Inadequate Glycemic Control With Insulin Therapy Alone
- Conditions
- Type 1 Diabetes Mellitus (T1DM)High Level of Sugar (Glucose) in the Blood
- Interventions
- Drug: Placebo
- First Posted Date
- 2015-08-21
- Last Posted Date
- 2020-02-12
- Lead Sponsor
- Lexicon Pharmaceuticals
- Target Recruit Count
- 1405
- Registration Number
- NCT02531035
- Locations
- π¬π§
Lexicon Investigational Site, Northampton, United Kingdom